INNATE PHARMA SA (IDD.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDD - FR0010331421 - Common Stock
1.488 EUR
-0.1 (-6.06%)
We assign a fundamental rating of 1 out of 10 to IDD. IDD was compared to 86 industry peers in the Biotechnology industry. Both the profitability and financial health of IDD have multiple concerns. IDD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- IDD had negative earnings in the past year.
- IDD had a negative operating cash flow in the past year.
- In the past 5 years IDD always reported negative net income.
- In the past 5 years IDD always reported negative operating cash flow.
1.2 Ratios
- IDD has a worse Return On Assets (-49.55%) than 63.95% of its industry peers.
- IDD's Return On Equity of -895.24% is on the low side compared to the rest of the industry. IDD is outperformed by 66.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- IDD has a Gross Margin of 49.52%. This is comparable to the rest of the industry: IDD outperforms 50.00% of its industry peers.
- IDD's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for IDD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
2. Health
2.1 Basic Checks
- IDD does not have a ROIC to compare to the WACC, probably because it is not profitable.
- IDD has more shares outstanding than it did 1 year ago.
- IDD has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for IDD is higher compared to a year ago.
2.2 Solvency
- IDD has an Altman-Z score of -6.46. This is a bad value and indicates that IDD is not financially healthy and even has some risk of bankruptcy.
- IDD has a worse Altman-Z score (-6.46) than 72.09% of its industry peers.
- IDD has a Debt/Equity ratio of 11.55. This is a high value indicating a heavy dependency on external financing.
- IDD has a worse Debt to Equity ratio (11.55) than 66.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.55 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.46 |
ROIC/WACCN/A
WACC6.4%
2.3 Liquidity
- IDD has a Current Ratio of 2.21. This indicates that IDD is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.21, IDD perfoms like the industry average, outperforming 46.51% of the companies in the same industry.
- IDD has a Quick Ratio of 2.21. This indicates that IDD is financially healthy and has no problem in meeting its short term obligations.
- IDD has a Quick ratio (2.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.21 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- The earnings per share for IDD have decreased strongly by -30.42% in the last year.
- Looking at the last year, IDD shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.
- Measured over the past years, IDD shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
3.2 Future
- IDD is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.32% yearly.
- IDD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.93% yearly.
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IDD. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- IDD's earnings are expected to decrease with -3.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
5. Dividend
5.1 Amount
- IDD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INNATE PHARMA SA / IDD.DE FAQ
Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?
ChartMill assigns a fundamental rating of 1 / 10 to IDD.DE.
Can you provide the valuation status for INNATE PHARMA SA?
ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IDD.DE). This can be considered as Overvalued.
How profitable is INNATE PHARMA SA (IDD.DE) stock?
INNATE PHARMA SA (IDD.DE) has a profitability rating of 0 / 10.
Can you provide the financial health for IDD stock?
The financial health rating of INNATE PHARMA SA (IDD.DE) is 2 / 10.